en · de · es · fr · pt
tb-500-notes.peptides6823.com › Data › Tb-500 Background And Identity — Common Mistakes

Tb-500 Background And Identity — Common Mistakes

By Editorial Desk · published 2026-05-18 · last reviewed 2026-06-05 · Data

The short version of actin binding fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2026-06-05. Anything still debated is marked as such rather than presented as settled.

TB-500 Background and Identity

The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.

Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.

TB-500 Identity and Naming Background

TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.

Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.

Tb-500 at a glance

PropertyValueNotes
AppearanceWhite to off-white lyophilized powderTypical form for short synthetic peptides
Solubility classFreely soluble in water and aqueous bufferDissolution aided by gentle mixing, not vigorous shaking
Typical storage temperature−20 °C, desiccated−80 °C used for long-term holding
Common analytical methodReverse-phase HPLC with UV detection near 214 nmIdentity confirmed separately by mass spectrometry
Common synonymsThymosin beta-4 fragment; TB4 fragmentNaming varies between suppliers and publications

TB-500 Identity and Molecular Background

TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.

Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.

Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.

Related pages on this site

Identity and Research Background

Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.

Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.

Thymosin Beta-4 Fragment Overview

The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.

TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.

Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.

Supporting material

=== No development reported === ADX-71149 (JNJ-1813; JNJ-40411813; JNJ-mGluR2-PAM) – metabotropic glutamate mGlu2 receptor positive allosteric modulator [5] Tebideutorexant (JNJ-61393215; JNJ-3215) – orexin OX1 receptor antagonist [6]

Impaired wound healing and thrombocytopenia are possible side effects of sirolimus; therefore, some transplant centers prefer not to use it immediately after the transplant operation, but instead administer it only after a period of weeks or months. Its optimal role in immunosuppression has not yet been determined, and it remains the subject of a number of ongoing clinical trials.

In cases of chronic arsenic exposure, the nitric oxide levels are depleted, due to the superoxide reactions. The enzyme NO synthase (NOS) uses L-arginine to form nitric oxide, but this enzyme is inhibited by monomethylated arsenic (III) compounds.

Sources: en.wikipedia.org

Supporting material

A number of trials were conducted by the Chinese government resulting in two executions, three sentences of life imprisonment, two 15-year prison sentences, and the firing or forced resignation of seven local government officials and the Director of the Administration of Quality Supervision, Inspection and Quarantine (AQSIQ). The former chairwoman of China's Sanlu dairy was sentenced to life in prison. In late October 2008, similar adulteration with melamine was discovered in eggs and possibly other foods. The source was traced to melamine being added to animal feed, despite a ban imposed in June 2007 following the scandal over pet food ingredients exported to the United States.

If this arrangement is clockwise, it is assigned an R configuration; if it is counterclockwise, it is assigned an S configuration. In contrast, steroid nomenclature uses α and β to denote stereochemistry at chiral centers. The α and β designations are based on the orientation of substituents relative to each other in a specific ring system. In general, α refers to a substituent that is oriented towards the plane of the ring system, while β refers to a substituent that is oriented away from the plane of the ring system. In steroids drawn from the standard perspective used in this paper, α-bonds are depicted on figures as dashed wedges and β-bonds as solid wedges. The name "11-deoxycortisol" is an example of a derived name that uses cortisol as a parent structure without an oxygen atom (hence "deoxy") attached to position 11 (as a part of a hydroxy group). The numbering of positions of carbon atoms in the steroid nucleus is set in a template found in the Nomenclature of Steroids that is used regardless of whether an atom is present in the steroid in question. Unsaturated carbons (generally, ones that are part of a double bond) in the steroid nucleus are indicated by changing -ane to -ene. This change was traditionally done in the parent name, adding a prefix to denote the position, with or without Δ (Greek capital delta) which designates unsaturation, for example, 4-pregnene-11β,17α-diol-3,20-dione (also Δ4-pregnene-11β,17α-diol-3,20-dione) or 4-androstene-3,11,17-trione (also Δ4-androstene-3,11,17-trione).

Concentrated or strong bases are caustic on organic matter and react violently with acidic substances. Aqueous solutions or molten bases dissociate into ions and conduct electricity. Reactions with indicators: bases turn red litmus paper blue, phenolphthalein pink, keep bromothymol blue in its natural colour of blue, and turn methyl orange-yellow. The pH of a basic solution at standard conditions is greater than seven. Bases are bitter.

Sources: en.wikipedia.org

Supporting material

Participants reported visual hallucinations, fewer auditory hallucinations and specific physical sensations progressing to a sense of bodily dissociation, as well as experiences of euphoria, calm, fear, and anxiety. These dose-dependent effects match well with anonymously posted "trip reports" online, where users report "breakthroughs" above certain doses. Strassman also highlighted the importance of the context where the drug has been taken. He claimed that DMT has no beneficial effects of itself, rather the context when and where people take it plays an important role. It appears that DMT can induce a state or feeling wherein the person believes they "communicate with other intelligent lifeforms" (see "Entity encounters" below). High doses of DMT produce a state that involves a sense of "another intelligence" that people sometimes describe as "super-intelligent", but "emotionally detached". A 1995 study by Adolf Dittrich and Daniel Lamparter found that the DMT-induced altered state of consciousness (ASC) is strongly influenced by habitual rather than situative factors. In the study, researchers used three dimensions of the APZ questionnaire to examine ASC. The first dimension, oceanic boundlessness (OB), refers to dissolution of ego boundaries and is mostly associated with positive emotions. The second dimension, anxious ego-dissolution (AED), represents a disordering of thoughts and decreases in autonomy and self-control. Last, visionary restructuralization (VR) refers to auditory/visual illusions and hallucinations.

Falkenrath; Paul Taylor, director of chemical and biological defence at Porton Down; the National Domestic Preparedness Consortium in the US; General John Doesburg, of the Chemical & Biological Defense Command; Conor Egleston of Southampton General Hospital; on 10 April 1972 the Biological Weapons Convention was signed by the UK, the US and the Soviet Union, but the West suspected that the Soviet Union would still continue its research, which was proved when microbiologist Ken Alibek defected in 1992, who worked at the Stepnogorsk Scientific and Technical Institute for Microbiology in Kazakhstan; the Soviets had around 25,000 scientists on their bio-warfare programme in the 1980s; Eric Henchal of the United States Army Medical Research Institute of Infectious Diseases; the Iraqi biological weapons program had a site that made anthrax, which was discovered after Iraqi microbiologist Rihab Taha disclosed the vast scale of Iraqi manufacture of bioweapons; in 1998 Iraq blocked UN inspectors to its bioweapons plants, so the UK and the US bombed these plants; the USS Mitscher (DDG-57); the monkeypox virus; CODIS, the Combined DNA Index System, run by the FBI, which had allowed scientists to know if a criminal was black, white, Hispanic or native American, through genetic markers; microbiologist Ellen Vitetta of the University of Texas Southwestern Medical Center.

== Effects on animals == The biological activity in animals of PMTX was first tested on lobsters by administering it to the neuromuscular synapse in the legs. 10mM of α-PMXT and β-PMXT each was administered, and both toxins enhanced the excitatory postsynaptic potentials (EPSPs). Enhancement of the EPSPs generates oscillatory spike responses and results in longer and larger depolarisations of the muscle membrane which will cause muscle contraction. The β-PMXT is proven to be 5 times more potent than the α-PMXT. The effect of β-PMXT on rat hippocampal CA1 interneurons is proven to be sodium channel modulation, this modulation is due to the toxin slowing the inactivation process of the sodium channels. It is also seen that the effect of the PMTX differs between different cell types, this can be explained by the different distribution of voltage-gated sodium channels in the cell types. In 2016 Konno et.al. experimented with the effect of pompilidotoxins on one insect and seven mammalian voltage-gated sodium channels. From the mammalian sodium channels the Nav1.6 channel gave the most potent effect which indicates that the toxin is selective for this channel. The channel of the insect that was tested for the toxin gave an even greater effect, which is quite logical since the spider wasps target arthropods. The toxin has not yet been tested on arachnids, though it is known that pompilidotoxins are used by spider wasps to paralyse arachnids.

=== Names === Etifoxine is the generic name of the drug and its INNTooltip International Nonproprietary Name, BANTooltip British Approved Name, and DCFTooltip Dénomination Commune Française. It is also known by the older and much-lesser-used synonym etafenoxine and by its developmental code name Hoe 36801. Etifoxine is marketed under the brand name Stresam. It has also been marketed under the brand name Strezam.

Sources: en.wikipedia.org

Frequently asked questions

What is TB-500?

TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.

Is TB-500 identical to thymosin beta-4?

Not necessarily. Some vendors use the name for the full 43-residue protein, while others apply it to a short actin-binding fragment or to a related tetrapeptide. The sequence should be confirmed from documentation rather than assumed from the label.

Is TB-500 an approved medicine?

No thymosin beta-4 fragment holds marketing approval as a medicine in major jurisdictions. Material offered for sale is typically labelled for laboratory research only.

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.

Network